Research Journal of Biological Sciences
ISSN: Online 1993-6087ISSN: Print 1815-8846
84
Views
0
Downloads
Synergistic Effect of Combined Etodolac Plus 5-Fluorouracil in Human Hepatoma Therapy--an In vitro Evaluation by Cell Lines HepG2, HA22T and KELFIB
Chiu Lan Hsieh , Chiung-Huei Peng , George T. Hsiao , Hui Er Wang , Wan-Shen Ko and Robert Y. Peng
Page: 268-279 | Received 21 Sep 2022, Published online: 21 Sep 2022
Full Text Reference XML File PDF File
Abstract
Hepatocellular Cancer Cell (HCC) lines HepG2, HA22T and KEL FIB were used to test the therapeutic effect of different combined protocols for etodolac plus 5-FU: 1). the selective COX 2 inhibitor etodolac alone at 0.0~0.16 µg µL 1; 2). 5-FU alone at 0.0~1.25 µg mL 1; 3). etodolac (0.31 µg µL 1) plus 5-FU (1.25 µg mL 1) in a simultaneous-, or an alternative sequential protocol. Cell viability was measured using MTT assay and flow cytometric analysis. An inverse dose dependent survival rate was observed for both drugs, while the apoptotic data of the three HCC cell lines have favored the simultaneous administration of etodolac plus 5-FU, which revealed to be more effective than administering etodolac or 5-FU alone. We conclude that in view of the therapeutic efficacy with a minimized cytotoxicity, a simultaneous administration of etodolac plus 5-FU, each at much more reduced dosages than usually prescribed alone, could be strongly recommended for treatment of HCC.
How to cite this article:
Chiu Lan Hsieh , Chiung-Huei Peng , George T. Hsiao , Hui Er Wang , Wan-Shen Ko and Robert Y. Peng . Synergistic Effect of Combined Etodolac Plus 5-Fluorouracil in Human Hepatoma Therapy--an In vitro Evaluation by Cell Lines HepG2, HA22T and KELFIB.
DOI: https://doi.org/10.36478/rjbsci.2007.268.279
URL: https://www.makhillpublications.co/view-article/1815-8846/rjbsci.2007.268.279